Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Globus MedicalBSP:G2ME34 26 EV-to-EBIT is 1.29 as of Aug. 11, 2026, which is 95% below its 10-year median of 27.82. GuruFocus rates BSP:G2ME34 with a GF Score™ of 26/100 and a GF Value™ of R$58.52 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 473 Medical Devices & Instruments companies, Globus Medical ranks better than 57.93% on this metric.
The historical rank and industry rank for Globus Medical's EV-to-EBIT or its related term are showing as below:
BSP:G2ME34'
s EV-to-EBIT Range Over the Past 10 Years
Min: 10.23 Med: 27.82 Max: 69.59
Current: 1.34
During the past 13 years, the highest EV-to-EBIT of Globus Medical was 69.59. The lowest was 10.23. And the median was 27.82.
BSP:G2ME34's EV-to-EBIT is ranked better than 57.93% of 473
companies
in the Medical Devices & Instruments industry
Industry Median: 19.01
vs BSP:G2ME34: 1.34
Globus Medical (BSP:G2ME34) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Globus Medical's Enterprise Value for the quarter that ended in Jun. 2026 was R$0 Mil.
Globus Medical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$3,562 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Globus Medical EV-to-EBIT Related Terms
Globus Medical EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Globus Medical's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:G2ME34 vs PODD, BRKR, GKOS: EV-to-EBIT Comparison
For the Medical Devices subindustry, Globus Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Globus Medical EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Globus Medical's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Globus Medical's EV-to-EBIT falls into.
Globus Medical's current Enterprise Value is R$4,587 Mil.
Globus Medical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$3,562 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Globus Medical (BSP:G2ME34) has a EV-to-EBIT of 1.29 as of Aug. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Globus Medical and its competitors. This is 95% below median its historical median of 27.82. Over the past decade, Globus Medical's EV-to-EBIT has ranged from 10.23 to 69.59. According to the industry distribution chart, Globus Medical ranks #199 out of 473 companies in the Medical Devices & Instruments industry, placing it in the top 42.1%.
Is Globus Medical's EV-to-EBIT too high?
Globus Medical's current EV-to-EBIT of 1.29 is 95% below median its 10-year median of 27.82. Over the past 10 years, this metric has ranged from a low of 10.23 to a high of 69.59. The Medical Devices & Instruments industry median EV-to-EBIT is 19.01. Globus Medical's value of 1.29 is 93.2% below this industry median. Based on the distribution chart, Globus Medical ranks #199 out of 473 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Globus Medical has a GF Score™ of 26/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Globus Medical's EV-to-EBIT compare to PODD and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Globus Medical ranks #199 out of 473 companies for EV-to-EBIT. This puts Globus Medical in the upper half of its industry. The industry median EV-to-EBIT is 19.01. Globus Medical's value of 1.29 is 93.2% below this benchmark. Historically, Globus Medical's own EV-to-EBIT has ranged from 10.23 to 69.59 over the past decade. While the company's 10-year median is 27.82 vs. the industry median of 19.01, Globus Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.01, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Globus Medical's current EV-to-EBIT of 1.29 is 93.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Globus Medical and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Globus Medical's current EV-to-EBIT is 1.29, which is 95% below median its own 10-year median of 27.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Globus Medical stock overvalued right now?
Based on GuruFocus' analysis, Globus Medical (BSP:G2ME34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$58.52, compared to a current price of R$52.00 — trading 11.1% below its estimated fair value. The current EV-to-EBIT is 1.29, which is 95% below median its 10-year median of 27.82 and 93.2% below the Medical Devices & Instruments industry median of 19.01. Globus Medical's overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Globus Medical (BSP:G2ME34), the current EV-to-EBIT is 1.29 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Globus Medical (BSP:G2ME34) Overvalued in 2026?
Based on GuruFocus' analysis, Globus Medical stock appears to be undervalued.
The current stock price of R$52.00 is trading 11.1% below its estimated GF Value™ of R$58.52.
GuruFocus considers Globus Medical to be Modestly Undervalued.
Key valuation signals for BSP:G2ME34:
EV-to-EBIT: 1.29 (95% below median its 10-year median of 27.82)
GF Value™: R$58.52 vs. price of R$52.00 (11.1% below fair value)
Industry Position: 93.2% below the Medical Devices & Instruments median (#199 of 473)
No single metric tells the full story. See the BSP:G2ME34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
26GF Score
Get the complete analysis for BSP:G2ME34
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:G2ME34 has been successfully added to your 
